YUYUE MEDICAL(SZ:002223) Huafu Securities·2025-05-24 15:10Investment Rating - The investment rating for the company is "Buy" [6][22]. Core Views - The company reported a revenue of 7.566 billion yuan for 2024, a decrease of 5.09% year-on-year, and a net profit of 1.806 billion yuan, down 24.63% year-on-year. For Q1 2025, the revenue was 2.436 billion yuan, an increase of 9.17% year-on-year, while the net profit was 625 million yuan, a decrease of 5.26% year-on-year [3][4]. - The blood glucose management and POCT solutions segment saw a revenue increase of 40.20% to 1.03 billion yuan in 2024, with CGM sales more than doubling. However, the respiratory segment experienced a decline of 22.42% to 2.597 billion yuan due to high base effects from the pandemic [4][5]. - The company anticipates a recovery in profitability in 2025 as revenue growth is expected to improve, following a challenging 2024 where gross margin decreased to 50.14% [5][6]. Financial Summary - The company’s revenue projections for 2025 to 2027 are 8.67 billion yuan, 9.856 billion yuan, and 11.127 billion yuan, representing year-on-year growth rates of 15%, 14%, and 13% respectively. The net profit projections for the same years are 2.037 billion yuan, 2.362 billion yuan, and 2.677 billion yuan, with growth rates of 13%, 16%, and 13% respectively [6][7]. - The company’s domestic sales were 6.574 billion yuan in 2024, a decrease of 8.58% year-on-year, while international sales reached 949 million yuan, an increase of 30.4% year-on-year, indicating strong growth in overseas markets [5][6].